You can buy or sell Affimed and other stocks, options, ETFs, and crypto commission-free!
Affimed N.V., also called Affimed, is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. Read More The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Heidelberg, Baden Wuerttemberg
52 Week High
52 Week Low
Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019
Heidelberg, Germany, March 20, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it will host a conference call on Wednesday, March 27, 2019 at 8:30 a.m. ET to discuss its full year 2018 financial results and corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 631 510 7495 for U.S. callers, or +44 (0) 2071 928000 fo...
Seeking AlphaMar 19
Affimed up 9% premarket on milestone payment
Affimed N.V. (NASDAQ:AFMD) will receive a payment in an undisclosed amount on achieving preclinical milestone under its ongoing strategic collaboration with Genentech, a member of the Roche Group.
Associated PressMar 19
Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. Heidelberg, Germany, March 19, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that the Company will re...
-$0.18 per share
Expected Mar 26, Pre-Market